Avapritinib Demonstrates Benefit in Patients With Advanced GIST
A phase 1/2 clinical study of avapritinib (Ayvakit®) in patients with advanced gastrointestinal stromal tumor (GIST) demonstrated its safety and anti-tumor activity. The results were reported by CStone Pharmaceuticals, a biopharmaceutical company researching and developing avapritinib with Blueprint Medicines, at the virtual European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2021. The…
